Search

Search Constraints

You searched for: Author/Creator Docherty, Kieran F.

Search Results

3. Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF. (15th September 2020)

4. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF. (24th November 2021)

5. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Issue 20 (18th May 2021)

6. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. (7th November 2022)

7. Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF. (6th February 2022)

8. Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. (3rd March 2022)

9. Effect of dapagliflozin on anaemia in DAPA‐HF. (22nd March 2021)

10. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Issue 17 (27th October 2020)